Currently the clinical trial to study the proprietary T-MSC (IMS001) cell therapy in patients with multiple sclerosis is under way.
IMS001 is a human embryonic stem cell-derived mesenchymal stem cell (hESC-MSC) based investigational drug. The Phase I study is enrolling patients who meet the following criteria
Provide signed and dated informed consent in accordance with local regulations
18 to 65 years of age
Diagnosis of multiple sclerosis
Has had an inadequate response to disease modifying treatments
EDSS (Expanded Disability Status Scale) within protocol parameters
Able and willing to undergo MRIs (Magnetic Resonance Imaging) and must be clinically stable for one month prior to Day One
Participants in this Phase I study will receive a single dose of IMS001 infusion by intravenous administration.
If you are a patient who is interested in accessing our investigational cell therapies, you can do so by participating in our clinical trials. We encourage you to discuss with your doctor first about whether you would be qualified for our clinical trials.
You may also find out more information about our ongoing clinical trials by going to the website
https://www.clinicaltrials.gov/ (Trial Identifier/Record Number: NCT04956744)